成人2型糖尿病:SGLT-2抑制剂或GLP-1受体激动剂的临床实践指南
该指南由国际专家组采用GRADE方法制定,针对成人2型糖尿病患者,按心血管和肾脏风险分层,给出SGLT-2抑制剂或GLP-1受体激动剂的弱或强推荐。证据来自764项随机试验的网状Meta分析,显示两类药物总体降低死亡、心肌梗死及终末期肾病风险,绝对获益随基线风险升高而增大。
要点
- 无 established CVD 或 CKD 且心血管危险因素≤3个:弱推荐不启动 SGLT-2 抑制剂或 GLP-1 受体激动剂。
- 有 established CVD 或 CKD:弱推荐启动 SGLT-2 抑制剂和 GLP-1 受体激动剂。
- 同时有 established CVD 和 CKD:强推荐启动 SGLT-2 抑制剂,弱推荐启动 GLP-1 受体激动剂。
核心结论
- 对成人2型糖尿病患者,SGLT-2抑制剂和GLP-1受体激动剂的心肾获益推荐应按心血管和肾脏风险分层。
- 同时有 established CVD 和 CKD 者,强推荐启动 SGLT-2 抑制剂。
研究设计与样本
- 国际专家组(含患者、临床医生和方法学家)遵循可信指南标准并采用 GRADE 方法制定。
- 证据基于一项联动系统综述与网状Meta分析,纳入764项随机试验、421 346名参与者。
主要发现
- SGLT-2抑制剂和GLP-1受体激动剂通常降低总体死亡、心肌梗死及终末期肾病或肾衰竭发生率(中至高质量证据)。
- 两类药物对卒中、心力衰竭住院及关键不良事件的影响在不同亚组中存在差异。
- 绝对获益随个体风险变化较大,例如每1000例治疗5年,最低风险者减少5例死亡,最高风险者减少48例死亡。
关键数值与推荐
- 无 established CVD 或 CKD 且心血管危险因素≤3个:弱推荐不启动 SGLT-2 抑制剂或 GLP-1 受体激动剂。
- 无 established CVD 或 CKD 但心血管危险因素>3个:弱推荐启动 SGLT-2 抑制剂,弱推荐不启动 GLP-1 受体激动剂。
- 有 established CVD 或 CKD:弱推荐启动 SGLT-2 抑制剂和 GLP-1 受体激动剂。
- 同时有 established CVD 和 CKD:强推荐启动 SGLT-2 抑制剂,弱推荐启动 GLP-1 受体激动剂。
- 对致力于进一步降低 CVD 和 CKD 风险者:弱推荐启动 SGLT-2 抑制剂而非 GLP-1 受体激动剂。
临床怎么用
- 临床医生可使用可信风险计算器(如 RECODe)识别患者个体心血管和肾脏结局风险。
- 互动证据摘要和决策辅助工具可支持知情治疗选择,包括共享决策。
局限性
- 预后综述仅识别14个合格风险预测模型,其中RECODe为多数基线风险估计提供信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CLINICAL QUESTION: What are the benefits and harms of sodium-glucose cotransporter 2 (SGLT-2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists when added to usual care (lifestyle interventions and/or other diabetes drugs) in adults with type 2 diabetes at different risk for cardiovascular and kidney outcomes? CURRENT PRACTICE: Clinical decisions about treatment of type 2 diabetes have been led by glycaemic control for decades. SGLT-2 inhibitors and GLP-1 receptor agonists are traditionally used in people with elevated glucose level after metformin treatment. This has changed through trials demonstrating atherosclerotic cardiovascular disease (CVD) and chronic kidney disease (CKD) benefits independent of medications' glucose-lowering potential. RECOMMENDATIONS: The guideline panel issued risk-stratified recommendations concerning the use of SGLT-2 inhibitors or GLP-1 receptor agonists in adults with type 2 diabetes• Three or fewer cardiovascular risk factors without established CVD or CKD: Weak recommendation against starting SGLT-2 inhibitors or GLP-1 receptor agonists.• More than three cardiovascular risk factors without established CVD or CKD: Weak recommendation for starting SGLT-2 inhibitors and weak against starting GLP-1 receptor agonists.• Established CVD or CKD: Weak recommendation for starting SGLT-2 inhibitors and GLP-1 receptor agonists.• Established CVD and CKD: Strong recommendation for starting SGLT-2 inhibitors and weak recommendation for starting GLP-1 receptor agonists.• For those committed to further reducing their risk for CVD and CKD outcomes: Weak recommendation for starting SGLT-2 inhibitors rather than GLP-1 receptor agonists. HOW THIS GUIDELINE WAS CREATED: An international panel including patients, clinicians, and methodologists created these recommendations following standards for trustworthy guidelines and using the GRADE approach. The panel applied an individual patient perspective. THE EVIDENCE: A linked systematic review and network meta-analysis (764 randomised trials included 421 346 participants) of benefits and harms found that SGLT-2 inhibitors and GLP-1 receptor agonists generally reduce overall death, and incidence of myocardial infarctions, and end-stage kidney disease or kidney failure (moderate to high certainty evidence). These medications exert different effects on stroke, hospitalisations for heart failure, and key adverse events in different subgroups. Absolute effects of benefit varied widely based on patients' individual risk (for example, from five fewer deaths in the lowest risk to 48 fewer deaths in the highest risk, for 1000 patients treated over five years). A prognosis review identified 14 eligible risk prediction models, one of which (RECODe) informed most baseline risk estimates in evidence summaries to underpin the risk-stratified recommendations. Concerning patients' values and preferences, the recommendations were supported by evidence from a systematic review of published literature, a patient focus group study, a practical issues summary, and a guideline panel survey. UNDERSTANDING THE RECOMMENDATION: We stratified the recommendations by the levels of risk for CVD and CKD and systematically considered the balance of benefits, harms, other considerations, and practical issues for each risk group. The strong recommendation for SGLT-2 inhibitors in patients with CVD and CKD reflects what the panel considered to be a clear benefit. For all other adults with type 2 diabetes, the weak recommendations reflect what the panel considered to be a finer balance between benefits, harms, and burdens of treatment options. Clinicians using the guideline can identify their patient's individual risk for cardiovascular and kidney outcomes using credible risk calculators such as RECODe. Interactive evidence summaries and decision aids may support well informed treatment choices, including shared decision making.
引用
- Li S, Vandvik PO, Lytvyn L, et al. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline. BMJ. 2021. PMID: 33975892. doi:10.1136/bmj.n1091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。